TAK vs SNY
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
TAK · Takeda Pharmaceutical$21.02 ▼ 0.80%
SNY · Sanofi$47.04 ▲ 0.28%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- TAK +55.9%
- SNY -2.0%
Head to head
| Metric | TAK | SNY |
|---|---|---|
| Price | $21.02 | $47.04 |
| Change today | ▼ 0.80% | ▲ 0.28% |
| Market cap | $67.36B | $112.71B |
| Return, 3 months | +19.8% | +8.2% |
| Return, year to date | +37.1% | +2.4% |
| Return, 1 year | +56.5% | 0.0% |
| P/E (TTM) | 296.1 | 24.1 |
| P/B | 1.4 | 1.4 |
| P/E percentile vs own 5y | 100th | 84th |
| Dividend yield | 1.49% | 4.99% |
| Revenue growth (YoY, latest qtr) | +6.7% | +15.7% |
| Net profit growth (YoY) | +1,740.9% | +7.9% |
| Gross margin | 65.8% | 73.4% |
| Operating margin | 14.3% | 21.6% |
| Net margin | 0.9% | 8.2% |
| Return on equity | 0.6% | 5.7% |
| Analyst target vs. price | +104.1% | +21.2% |
| Analyst buy share | 100% | 0% |
| RSI (14) | 69 | 73 |
| 30-day volatility | 23.6% | 28.2% |
| Max drawdown, 1 year | -19.9% | -21.1% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Hold |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SNY is the largest of the group by market value.
- TAK has returned the most over the past year.
- SNY carries the lowest trailing P/E.
- SNY pays the highest dividend yield.
- SNY is growing revenue fastest.
- SNY keeps the most profit per dollar of sales.
- TAK has been the calmest stock over the last 30 days.